The latest news, views and analysis from the pharmaceutical industry’s frontline in the war on cancer. Updates on pharmaceutical and biotech oncology pipelines, regulatory decisions and market access news, and how healthcare systems needs to change to tackle one of the world’s biggest killers.
First ever targeted agent in renal cell carcinoma could be strong addition to AZ oncology portfolio
New cancer tech devices for oncology screening, diagnosis and mental wellbeing.
Assessing the global challenges inhibiting immuno-oncology market access.
Complex and evolving cancer treatment pathways require comprehensive and tailored support programmes.
Partnerships, co-marketing and the positioning of drugs are shaping the competitive landscape in oncology.
Lilly’s drug will be re-appraised in 2020
Data sets AZ up to file Lynparza in new indication
Tesara and Takeda among other companies to publish data.
For the first time, FDA approves drug on the basis of biomarkers, rather than location.